2m 2m 2m 2m 2m 2m 2m
ATRIUM THERAP (RNA)
NASDAQ
$12.90-$0.04 (-0.31%)
Price as of Jun 23, 2026 11:45 AM EDT- $221.3MMarket Cap
- -55.61%1-Year Change
- BiotechnologyIndustry
ATRIUM THERAP (RNA)
$12.90-$0.04 (-0.31%)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 46
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
No data found
Peers
Statistics
MoreDay Range
$12.59
$12.96
$12.94
1-Year Range
$11.55
$72.93
$12.94
Latest Close$12.94
Change
+$0.28 (+2.16%)
Volume221,017
Market Cap$221.3M
Shares Outstanding17.1M
P/E (TTM)-13.31
Diluted EPS (TTM)-$0.97
Enterprise Value-$46.5M
Information as of 06/22/2026
Company Profile
ATRIUM THERAPEUTICS INC
https://atriumtherapeutics.com$221.3M
Market Cap
-$16.6M
Net Income
Sector: Healthcare
Industry: Biotechnology
10578 Science Center Drive, San Diego, CA, United States, 92121
619 876 0700Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
Key Executives
- Stephanie Kenney
- Rocio Martin Hoyos
- Kathleen Gallagher
- Steven George Hughes
- Brendan Winslow
Current Ownership Distribution
- Institutions1.7B (79.87%)
- Mutual Funds405.0M (19.59%)
- Insiders11.2M (0.54%)
- Other0 (0.00%)